Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + nedaplatin + tegafur (Tiggio) as postoperative adjuvant therapy for oral cancer
ChiCTR2100048559Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Oral Mucosal Carcinoma, lingual carcinoma, Cancer of the Floor of the Mouth and 3 more, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: 2-year disease-free survival rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Oral Mucosal Carcinomalingual carcinomaCancer of the Floor of the MouthGingival cancer (GSCC)Buccal mucosa cancer
Beyond the preview
Go deeper on ChiCTR2100048559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048559.